Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (31-40 of 159) with videos related to

Pageof 16
Sort By:
Medical and Pediatric Oncology|January 1, 1992
Inadvertent intrathecal injection of daunorubicin with fatal outcomeM E Mortensen, A J Cecalupo, W D Lo, et al.
Cancer Treatment Reports|July 1, 1986
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolitesB E Cohen, M J Egorin, E A Kohlhepp, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT)P L Gutierrez, B E Cohen, G Sosnovsky, et al.
Biochemical Pharmacology|May 1, 1985
Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical speciesP L Gutierrez, M J Egorin, B M Fox, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and ratsM J Egorin, Z M Yuan, D L Sentz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1984
The murine metabolism and disposition of marcellomycinP Dodion, M J Egorin, J M Tamburini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapyR Sridhara, M A Eisenberger, V J Sinibaldi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1989
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamideB Subramanyam, P S Callery, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
Plasma kinetics of aclacinomycin A and its major metabolites in manM J Egorin, D Van Echo, B M Fox, et al.
Cancer Research|February 15, 1993
Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysisA D Harpalani, S W Snyder, B Subramanyam, et al.
Pageof 16

Showing results (31-40 of 159) with videos related to

Sort By:
Pageof 16
Medical and Pediatric Oncology|January 1, 1992
Inadvertent intrathecal injection of daunorubicin with fatal outcomeM E Mortensen, A J Cecalupo, W D Lo, et al.
Cancer Treatment Reports|July 1, 1986
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolitesB E Cohen, M J Egorin, E A Kohlhepp, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT)P L Gutierrez, B E Cohen, G Sosnovsky, et al.
Biochemical Pharmacology|May 1, 1985
Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical speciesP L Gutierrez, M J Egorin, B M Fox, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and ratsM J Egorin, Z M Yuan, D L Sentz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1984
The murine metabolism and disposition of marcellomycinP Dodion, M J Egorin, J M Tamburini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapyR Sridhara, M A Eisenberger, V J Sinibaldi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1989
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamideB Subramanyam, P S Callery, M J Egorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
Plasma kinetics of aclacinomycin A and its major metabolites in manM J Egorin, D Van Echo, B M Fox, et al.
Cancer Research|February 15, 1993
Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysisA D Harpalani, S W Snyder, B Subramanyam, et al.
Pageof 16